A phase I study to assess the safety and immunogenicity of Ad6NSmut and AdCh3NSmut in patients with hepatitis C virus infection.

Trial Profile

A phase I study to assess the safety and immunogenicity of Ad6NSmut and AdCh3NSmut in patients with hepatitis C virus infection.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2015

At a glance

  • Drugs Hepatitis C vaccine (Primary) ; Peginterferon; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 20 Mar 2015 Accrual to date 150% reported by United Kingdom Clinical Research Network record.
    • 06 May 2013 Planned end date changed from 1 Jun 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 04 Oct 2012 Planned End Date changed from 31 Dec 2011 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top